Why frontier labs are betting on biotech: OpenAI acquires Orchestra to accelerate drug R&D
MWCvitkovic · x · 2026-10-30
An analysis of why frontier labs are moving into biotech: OpenAI last week acquired Orchestra, the ops platform the author used to build his company's drug program, and Anthropic made a similar-adjacent move the same week. The thesis: 'Pipeline-in-a-Person' will help AI accelerate R&D.
More from AGI Musings
- littmath: recognizing AI risks in articles like this is a reason for (some) optimism — littmath · 2026-10-30
- Sonia Joseph to debate world models alongside Yann LeCun at MAIN conference — soniajoseph_ · 2026-10-30
- AI Agents Audit 138 Economics Papers, Flag 2,035 Potential Problems — haider1 · 2026-10-30
- Schmidhuber's 'Miraculous Year 1990-91': claiming roots of GANs, Transformers, pre-training — SchmidhuberAI · 2026-10-30
- Enterprise AI stalls in the messy middle: measure value, not activity — DavidLinthicum · 2026-10-30
- 18-year-old student puzzled: peers bash AI while heavily using it — ChaoticTotoWolff · 2026-10-30